Objectives: The aim of this study was to describe characteristics of perinatally HIVinfected adolescents (PHIVAs), factors associated with mortality, and outcomes at transition.
The aim of this study was to describe characteristics of perinatally HIVinfected adolescents (PHIVAs), factors associated with mortality, and outcomes at transition.
Design: Ongoing observational database collating clinical data on HIV-infected children and adolescents in Asia.
Methods: Data from 2001 to 2016 relating to adolescents (10-19 years) with perinatal HIV infection were analysed to describe characteristics at adolescent entry and transition and combination antiretroviral therapy (cART) regimens across adolescence. A competing risk regression analysis was used to determine characteristics at adolescent entry associated with mortality. Outcomes at transition were compared on the basis of age at cART initiation.
Results: Of 3448 PHIVA, 644 had reached transition. Median age at HIV diagnosis was 5.5 years, cART initiation 7.2 years and transition 17.9 years. At adolescent entry, 35.0% had CD4 þ cell count less than 500 cells/ml and 51.1% had experienced a WHO stage III/IV clinical event. At transition, 38.9% had CD4 þ cell count less than 500 copies/ml, and 53.4% had experienced a WHO stage III/IV clinical event. Mortality rate was 0.71 per 100 person-years, with HIV RNA !1000 copies/ml, CD4 þ cell count less than 500 cells/ml, height-for-age or weight-for-age z-score less than À2, history of a WHO stage III/IV clinical event or hospitalization and at least second cART associated with mortality. For transitioning PHIVA, those who commenced cART age less than 5 years had better virologic and immunologic outcomes, though were more likely to be on at least second cART.
Introduction
Accessibility to effective antiretroviral therapy (ART) has shifted the paradigm of HIV infection from a terminal illness to a chronic condition [1] . Infants with perinatally acquired HIV (PHIV) are surviving into adolescence and beyond, which brings with it the challenges of managing a chronic disease during a complex adolescent period of physical, psychological and social change [2] . Perinatally HIV-infected adolescents (PHIVAs) are subject to longterm exposure to potentially harmful processes related to life-long HIV infection, including direct viral cytopathic effects, chronic inflammation, immune-mediated phenomena and effects from ART [3] . The complex interplay of physiologic processes associated with HIV infection and its therapy in the context of adolescence makes this cohort susceptible to poor outcomes [4] , and ongoing epidemiologic studies are integral to inform HIV healthcare providers how to optimize the management of PHIVA.
Characteristics and treatment outcomes of children age more than 12 years with PHIV from the TREAT Asia Pediatric HIV Observational Database (TApHOD) cohort of IeDEA Asia-Pacific have been previously reported, which included data up to 2011 [5] . This study aims to provide an update and additional analyses on the characteristics, mortality and outcomes of PHIVA from the TApHOD cohort incorporating data up to 2016 and an adolescent age range of 10-19 years to reflect the WHO adolescent age group and facilitate comparison with other regional cohorts. Specifically assessing the characteristics of PHIVA as they enter adolescence and the impact on PHIVA mortality, the trends in combination ART (cART) across adolescence, the characteristics of those reaching transition to adult HIV services and outcomes at time of transition based on age at cART initiation.
Materials and methods

Study population
Details of the TApHOD cohort have been previously reported [6] . In brief, as of December 2016, there were 16 study sites across six countries in Asia (Cambodia¼1, India¼1, Indonesia¼2, Malaysia¼4, Thailand¼5 and Vietnam¼3) that collect data relating to HIV care, which are transferred to The Kirby Institute (University of New South Wales, Sydney, Australia) for data management and statistical analysis. For this study, any individual 10-19 years of age with PHIV who received care at a TApHOD site through to December 2016 was included. Ethics approval was obtained through the human research ethics committees at the participant sites, The Kirby Institute and the coordinating centre at TREAT Asia/amfAR (Bangkok, Thailand).
Definitions
The adolescent age range was defined as 10-19 years and childhood age range as less than 10 years. Adolescent entry was defined as their 10th birthday or age at first clinic visit for children who had their first clinic visit after their 10th birthday. ART was defined as treatment with any antiretroviral agent. cART was defined as a combination of at least three antiretroviral agents, consisting of either three nucleoside reverse transcriptase inhibitors (NRTIs) or at least three antiretroviral agents from at least two different drug classes. First cART was defined as the initial cART regimen. A switch to second cART was defined as a switch in cART that involved either a change in antiretroviral drug class; or the addition of a new antiretroviral drug class; or a change in at least two antiretroviral drugs. A suppressed HIV viral load was defined as less than 400 copies/ml, immune deficiency as a CD4 þ cell count of less than 500 cells/ml and severe immune deficiency as a CD4 þ cell count less than 200 cells/ml. Transition to an adult HIV service was determined by the participating site reporting transfer to an adult HIV clinical site, or transfer to any other site at least 16 years of age. Loss to follow-up (LTFU) was determined by either participant sites reporting LTFU or a more than 12-month absence of data from the date of last data transfer from participating sites. Weight-for-age z scores (WAZ) and height-for-age z scores (HAZ) were calculated using WHO 1977 Standards [7] and WHO 2007 Child Growth Standards [8, 9] , respectively.
Statistical analysis
Descriptive analyses were used to report the demographic, immunologic, virologic and clinical characteristics of PHIVA at adolescent entry and transition. For HIV viral load, CD4
þ cell count and growth parameters (WAZ and HAZ), observations that were closest to the respective time points within a 12-month window period were taken. If the date of HIV diagnosis was not available or if the date of HIV diagnostic testing was after study enrolment or ART initiation, then the earliest date available (either study enrolment or ART initiation) was considered the date of HIV diagnosis. Only the event with the highest WHO clinical stage experienced was recorded for each individual. Age at disclosure, LTFU and death were specified. The proportion of PHIVA on first or at least second (subsequent) cART regimen across adolescence were analysed on an intention-to-treat basis, with death, LTFU and transition considered censoring events. Mortality rates were determined by survival analysis with person-year observations calculated from adolescent entry to death, LTFU, transition, last reported clinic visit (if occurring at < 20 years of age) or 19.9 years of age (if remaining in active care !20 years of age). A competing risk regression analysis (Fine and Gray method) [10] , with LTFU as a competing event, was used to determine associations between characteristics at adolescent entry and mortality. Subdistribution hazard ratios (SHRs) were calculated for covariates, including sex; orphan status; primary caregiver; clinic setting; HIV viral load; CD4 þ cell count; tuberculosis (TB) infection; HAZ; WAZ; having experienced a WHO clinical event, ART adverse event or hospitalization; and age at cART initiation and cART regimen at adolescent entry. Covariates with a P value of less than 0.1 on univariate analysis were included in a multivariate analysis and adjusted SHR (aSHR) calculated. The multivariate analysis was conducted in a stepwise fashion maintaining covariates that retained a P value of less than 0.05. In analysing outcomes at transition, individuals were stratified by age at cART initiation (<5, 5-9, !10 years), the Kruskal-Wallis test was used for continuous variables, and chi-square or Fisher's exact test used for categorical variables. Unknown or missing data were included in the analyses as a separate category within each variable. Statistical analyses were performed using Stata, version 14.2 (StataCorp LP, College Station, Texas, USA).
Results
Characteristics of perinatally HIV-infected adolescent cohort As of December 2016, there were 5647 children and adolescents with PHIV who had received care within the TApHOD network. Of these, 3448 were aged 10-19 years and included in the study, with adolescent data ranging from 2001 to 2016. The median age at HIV diagnosis for the PHIVA cohort was 5. Perinatally HIV-infected adolescent mortality The overall mortality rate was 0.71 per 100 person-years [95% confidence interval (95% CI) 0.60-0.85]. For those enrolled in care by their 10th birthday, the mortality rate was 0.47 per 100-person years (95% CI 0.37-0.61), while for those enrolled in care after their 10th birthday, the mortality rate was 1.6 per 100-person years (95% CI 1.2-2.1). On multivariate analysis, the following characteristics at adolescent entry were found to be significant risk factors for adolescent mortality: HIV viral load at least 1000 copies/ml [1000-9999 copies/ml aSHR 3.2 (95% CI 1.2-8.4); !10 000 copies/ml aSHR 2.9 (95% CI 1.5-5.5)]; CD4 þ cell count less than 500 copies/ml [200-499 cells/ml aSHR 3.1 (95% CI 1. Trends in combination antiretroviral therapy across adolescence Figure 1 shows the relative proportion of PHIVA on first or subsequent (at least second) cART regimen across adolescence. At age 10 years (n ¼ 3448), there were 2117 (61.4%) PHIVA on their first cARTregimen, 637 (18.5%) on their subsequent cART regimen and 694 (20.1%) who had not commenced cART (i.e. either ART naive or receiving mono or dual therapy). For those who remained in active paediatric care through to age 19 years (n ¼ 544), there were 281 (51.7%) PHIVA who had continued their first regimen, 258 (47.4%) on a subsequent cART regimen and five (0.9%) who had not received cART.
PHIVA outcomes at transition based on age at combination antiretroviral therapy initiation Of the 644 PHIVA who had transitioned out of paediatric care, 39 (5.6%) had commenced cART at age less than 5 years, 309 (48.0%) at age 5-9 years, 289 (44.9%) at age at least 10 years and seven (1.1%) had not commenced cART prior to transition. When stratified by age at cART initiation (<5, 5-9, !10 years), there was a significantly higher proportion of PHIVA who had commenced cART at age less than 5 years with a suppressed HIV viral load (P ¼ 0.048) and CD4
þ cell count at least 500 cells/ml (P ¼ 0.003) at the time of transition (Table 3 ). In addition, there was a significantly lower proportion of those commencing cART at age less than 5 years on their first cARTregimen at the time of transition (P ¼ 0.046) ( Table  3 ). There were no significant differences in growth parameters, or history of a WHO clinical event or ART adverse event by time of transition.
Discussion
This study provides key insights into the characteristics of Asian PHIVA as they entered adolescence and the impact of their health on subsequent mortality, as well as outcomes for those surviving to transition to adult services. The delay in HIV diagnosis (median age 5.5 years) and cART initiation (median age 7.2 years) highlights issues regarding access to HIV diagnostics and treatment for infants in the Asian region. Given current standards of care advocate early infant diagnosis and cART initiation irrespective of immunologic and virologic status [11, 12] , these figures support ongoing efforts to strengthen the continuum of care from prevention of mother-to-child transmission programmes to paediatric HIV health services in Asia. These delays in HIV diagnosis and cART initiation contributed to the substantial cumulative morbidity encountered by our study cohort by the time they reached adolescence, with more than half having experienced a WHO stage III/IV Fig. 1 . Proportion of PHIVA on combination antiretroviral therapy across adolescence. cART, combination antiretroviral therapy; PHIVA, perinatally HIV-infected adolescent; subsequent cART regimen, ! second cART regimen. Values n (%) unless otherwise specified. cART, combination antiretroviral therapy; IQR, interquartile range. event. In addition, at least one in three were immune deficient at adolescent entry, highlighting the negative impact delayed diagnosis and cART initiation has on immune status [13] .
The mortality rate of 0.71 per 100 person-years calculated for our PHIVA cohort is similar to that reported in a South African PHIVA cohort (0.80 per 100 person-years) [14] , less than that reported in a Ugandan adolescent cohort (3.65 per 100 person-years) [15] , and more than that reported in PHIV youths from a combined Paediatric HIV/AIDS Cohort Study (PHACS) Adolescent Master Protocol (AMP) and the International Maternal Pediatric Adolescent AIDS Clinical Trials (IMPAACT) 1074 cohort (0.4 per 100 person-years) [16] . These comparisons demonstrate the context-specific nature of HIV outcomes, and the influence of health infrastructures on access to HIV diagnostics and ART, as well as long-term HIV health maintenance throughout adolescence [17] .
Our results demonstrated having a HIV viral load of more than 1000 copies/ml, a CD4 þ cell count of less than 500 cells/ml, poor growth, a history of a WHO stage III/ IV clinical event or hospitalization, and receiving at least their second cART regimen at adolescent entry to be associated with adolescent mortality. Aside from cART regimen, these features are indicative of poor disease control, and demonstrate the detrimental effects delayed HIV diagnosis and cART initiation in childhood has on longer term outcomes. The risk factors of uncontrolled viraemia and poor immune status on mortality are reflected in studies conducted in Thai national cohorts [18, 19] , and the majority of deaths in PHIV youths from the combined PHACS AMP and IMPAACT 1074 cohort occurred in the context of a HIV viral load at least 400 copies/ml and/or CD4 þ cell count less than 200 cells/ml [16] . The association between receiving at least second cART regimen and adolescent mortality could reflect issues with ART resistance, adherence, and/ or intolerances, leading to poorer outcomes, and supports the identified need to develop and implement strategies to optimize ART adherence [20, 21] , as well as ongoing efforts to optimize cART durability and tolerability. The fact that those who were cART naive at adolescent entry were not found to be at a higher risk of mortality may be due to them having less advanced disease.
Currently, there are limited epidemiologic data on outcomes for PHIVA reaching transition [22, 23] . For those who survived to transition, half had experienced a WHO stage III/IVevent, one in five had an ART adverse event and at least one in five had required hospitalization. In addition to the morbidity encountered, at least one in three were immune deficient. These immunologic outcomes are similar to that reported in Canada [24] , and better than that reported in the UK (where over half were immune deficient) [25] . This is concerning given the challenges to the care continuum that are encountered at the time of transition from paediatric to adult HIV services, and the negative impact this can have on the HIV health of the young adult. To add to the challenges surrounding transition is retention in care [24, 26] . The median age of LTFU in this study was 15.4 years, which is leading into the crucial period of transition, and re-enforces the need for youth-specific engagement strategies to ensure retention in care and to navigate the transition process [27] . Those who had commenced cART at age less than 5 years demonstrated better virologic and immunologic outcomes at the time of transition, which supports the role of early cART initiation. However, this subgroup was also most likely to undergo a regimen switch. The fact there was no significant difference at transition with regards to disease or treatment-related morbidity based on age at cART initiation could reflect a survival bias in that those surviving to transition are those with relatively stable disease. It is also possible that the 5-year categorizations may be too broad to detect a difference.
Almost half of those who had remained in active paediatric care through to 19 years of age had switched to at least their second cART regimen. These results signify the amount of ARTexposure across multiple drug classes, either due to treatment failure or ART intolerances, thereby narrowing future therapeutic options throughout adulthood, and highlight the need for better access to newer antiretroviral agents in resource-limited settings [28] . Given the move towards commencing cART on all children with PHIV as early as possible and the complexities in choosing subsequent cART regimens [29] , these figures, in conjunction with the association of receiving at least second cART and PHIVA mortality, highlights the importance of continuing evaluations on the durability and tolerability of first-line cART options.
Limitations of this study include inconsistent reporting and variable access to laboratory testing within sites over time and across sites leading to incomplete data. This could lead to transition events being unreported and classified as LTFU, unascertained mortality among those LTFU and the inability to determine whether regimens switches were based on treatment failure, ART intolerances or regimen simplification. There is also the potential for a survival bias associated with reporting mortality rates only for those who survived to adolescence and not the greater PHIV cohort.
In conclusion, this study highlights the substantial cumulative morbidity experienced by Asian PHIVA by adolescent entry and transition, and emphasizes the importance of virologic, immunologic and clinical disease control, as well as first-line cART durability/tolerability to minimise adolescent mortality. Commencing cART at age less than 5 years provided the best virologic and immunologic outcomes for PHIVA at transition, though they more likely to require to a regimen switch. Almost half of PHIVA remaining in paediatric care towards the end of adolescence were on at least their second cART regimen, providing impetus for ongoing efforts to optimize the durability and tolerability of cART regimens to preserve future therapeutic options, particularly in the era of early cART initiation.
